WUXI PHARMATECH (CAYMAN) INC. (ADR) SHANGHAI, January 8, 2016 /PRNewswire/ -- WuXi AppTec (WuXi), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology, and medical device industries, today congratulated Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (CTTQ), a well-established Chinese pharmaceutical company that is a subsidiary of Sino Biopharmaceutical Ltd., and Janssen Pharmaceuticals Inc. (Janssen), a leading global pharmaceutical company, for having reached an exclusive license agreement. Under this agreement, CTTQ grants Janssen rights to develop and commercialize an undisclosed immuno- modulating agent to treat chronic hepatitis B virus (HBV) infection globally outside China. Both CTTQ and Janssen are long-time collaboration partners of WuXi. In 2013, CTTQ signed a contract with WuXi to discover anti-HBV small-molecule drugs. WuXi provided end-to-end integrated research services on the compound that is the subject of this license agreement.
Hepatitis B is a serious and potentially fatal infectious disease afflicting more than 350 million patients worldwide. China has the world's largest hepatitis B patient population. Currently there is no cure for the disease, and effective new drugs are urgently needed.
"We congratulate CTTQ and Janssen on this important agreement," said Dr. Ge Li, Chairman and CEO of WuXi AppTec. "WuXi is proud to have played a part in this collaboration to bring an innovative drug candidate closer to hepatitis B patients in China and around the world."
About WuXi AppTec
WuXi AppTec is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States. As a research-driven and customer-focused company, WuXi provides pharmaceutical, biotechnology, and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi is also building a platform to provide clinical diagnostic services directly to physicians and their patients globally. WuXi's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D.
For more information, please contact: Aaron Shi
Director of Corporate Communications
+86-21 5046-4362
aaron_shi@wuxiapptec.com
WuXi PharmaTech (Cayman) Inc. issued this content on 2016-01-08 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 2016-01-12 13:58:02 UTC
Original Document: http://phx.corporate-ir.net/external.file?t=2&item=o8hHt16027g9XhJTr8+weNRYaV9bFc2rMd0Q/AXw4zt76bpz/yOnjmY2h8eWWbV6IDZvowY/A/CwEPCFdPMkfbfAGQNx4+SwGimKwzZMjED/Nz26aiXtZnYR0hGA5h4qqhrOhCK+bA0w3MnwPgjXVA==&cb=635882031820979518
